Tijen ONKOL, Zeynep ÖZDEMİR, Mehmet Abdullah ALAGÖZ, Yaren Nur ZENNİ, Tuba YILMAZ

QSAR and pharmacophore analysis on pyridazinone derivatives as acetylcholinesterase inhibitors

Aim: The aim of this study is to provide a qualitative and quantitative explanation of the structure activity relationships withpharmacophore analysis and Quantitative Structure Activity Relationship (QSAR) studies of the compounds synthesized asacetylcholinesterase enzyme inhibitor by our research group.Material and Methods: Maestro 11.9 (Schrödinger, New York) was used for pharmacophore model studies. Pharmacophore analysiswas performed for all compounds showing acetylcholine esterase inhibitory effect. For QSAR studies, various physicochemicalparameters of these compounds were calculated using GaussView 5.0 and ChemDraw 15.0 programs. Regression analysis wasperformed by using these parameters and QSAR equation was obtained.Results: All compounds overlapped and hypotheses generated. The most appropriate pharmacophore model was created bycomparing the hypothesis and activity results of the compounds. The analyses were performed using 8 different parameters for allcompounds. R2 value of equation was found 1.Conclusion: The pharmacophore analysis and the QSAR equation are applicable for all compounds synthesized as acetylcholinasteraseinhibitory and containing pyridazinon-2-ylacetohydrazide structure. Also, the estimated IC50 values can be calculated before thecompounds are synthesized using the QSAR equation.

PDF

___

1. Brookmeyer R, Abdalla N, Kawas CH, et al. Forecasting the prevalence of preclinical and clinical Alzheimer’s disease in the United States. Alzheimers Dement 2018;14:121-9.
2. Hampel H, Mesulam MM, Cuello AC, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 2018;14:1917- 33.
3. García-Font N, Hayour H, Belfaitah A, et al. Potent anticholinesterasic and neuroprotective pyranotacrines as inhibitors of beta-amyloid aggregation, oxidative stress and tauphosphorylation for Alzheimer’s disease. Eur J Med Chem 2016;118:178-92.
4. Ballard C, Gauthier S, Corbett A, et al. Alzheimer’s disease. Lancett 2011;377:1019-31.
5. Özdemir Z, Alagöz MA. Anticholinesterases. In: AlZwaini IJ, AL-Mayahi A, eds. Selected Topics in Myasthenia Graviz. 1st edition. London: Intech Open; 2019:69-78.
6. Chiu PY, Wei CY. Donepezil in the one-year treatment of dementia with Lewy bodies and Alzheimer’s disease. J Neurol Sci 2017;81:22.
7. Anand P, Singh P. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res 2013;36:375- 99.
8. Özdemir Z, Yılmaz H, Sarı S, et al. Design, synthesis, and molecular modeling of new 3(2H)- pyridazinone derivatives as acetylcholinesterase/ butyrylcholinesterase inhibitors. Med Chem Res 2017;26:2293-308.
9. Dal-Piaz V, Giovannoni MP, Ciciani G, et al. 4-Substituted-5-acetyl-2-methyl-6-phenyl-3(2H) pyridazinones as PGE2 and IL-1 release inhibitors from mouse adherent mac-rophages. Pharm Res 1994;29:367-72.
10. Franzen K, Saveman B, Blomqvist K. Advancing knowledge in cardiovascular nursing and the promotion of evidence-based clinical practice. Eur J Cardiovasc Nurs 2007;6:112-20.
11. Nieminen MS, Cleland JGF, Eha J, et al. Oral levosimendan in patients with severe chronic heart failure the persist study. Eur J Heart Fail 2008;10:1246- 54.
12. Sotelo E, Fraiz N, Yanez M, et al. Pyridazines. Part XXIX: synthesis and platelet aggregation inhibition activity of 5-sub-stituted-6-phenyl-3(2H)-pyridazinones. Novel aspects of their biological actions. Bioorg Med Chem 2002;10:2873-82.
13. Colovic MB, Krstic DZ, Lazarevic-Pasti TD, et al. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 2013;11:315-35.
14. Dvir H, Silman I, Harel M, et al. Acetylcholinesterase: from 3D structure to function. Chem Biol Interact 2010;187:10-22.
15. Özdemir Z, Özçelik AB, Uysal M. Approaches Based on Cholinergic Hypothesis and Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease. In: Rahman A, eds. Frontiers in Clinical Drug Research-Alzheimer Disorders. 1st edition. Sharjah: Bentham Science Publishers; 2019:8:154-90.
16. Hasselmo ME. The role of acetylcholine in learning and memory. Curr Opin Neurobiol 2006;16:710-5.
17. Fruhbeis H, Klein R, Wallmeier H. Computer-assisted molecular design (camd), an overview. Angew Chem Int Ed 1987;26:403-18.
18. Kubinyi H. QSAR and 3D QSAR in drug design. Part 1: methodology. Drug Discov Today 1997;2:457-67.
19. Yıldız I, Ertan T, Bolelli K, et al. QSAR and pharmacophore analysis on amides against drug-resistant S. aureus. SAR QSAR Environ Res 2008;19:101-13.
20. Önkol T, Gökçe M, Orhan İ, et al. Design, synthesis and evaluation of some novel 3(2H)-pyridazinone2-yl acetohydrazides as acetylcholinesterase and butyrylcholnesterase inhibitors. Org Commun 2013;6:55-67.